This company has been acquired
GreenLight Biosciences Holdings Past Earnings Performance
Past criteria checks 0/6
GreenLight Biosciences Holdings's earnings have been declining at an average annual rate of -41.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been growing at an average rate of 577.3% per year.
Key information
-41.7%
Earnings growth rate
93.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 577.3% |
| Return on equity | -717.2% |
| Net Margin | -1,521.0% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Revenue & Expenses BreakdownBeta
How GreenLight Biosciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 10 | -157 | 35 | 0 |
| 31 Dec 22 | 7 | -167 | 36 | 0 |
| 30 Sep 22 | 4 | -163 | 34 | 0 |
| 30 Jun 22 | 3 | -154 | 31 | 0 |
| 31 Mar 22 | 2 | -129 | 26 | 0 |
| 31 Dec 21 | 2 | -112 | 20 | 0 |
| 30 Sep 21 | 1 | -86 | 17 | 0 |
| 30 Jun 21 | 2 | -89 | 15 | 0 |
| 31 Mar 21 | 2 | -75 | 13 | 0 |
| 31 Dec 20 | 2 | -53 | 11 | 0 |
| 31 Dec 19 | 3 | -37 | 9 | 0 |
Quality Earnings: GRNA is currently unprofitable.
Growing Profit Margin: GRNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRNA is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.
Accelerating Growth: Unable to compare GRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-43.2%).
Return on Equity
High ROE: GRNA has a negative Return on Equity (-717.16%), as it is currently unprofitable.